Hostname: page-component-77c89778f8-m8s7h Total loading time: 0 Render date: 2024-07-17T07:48:05.987Z Has data issue: false hasContentIssue false
  • English
  • Français

The Ethics of Fecal Microbiota Transplant as a Tool for Antimicrobial Stewardship Programs

Published online by Cambridge University Press:  01 January 2021

Thomas S. Murray  and
Jennifer Herbst
Get access Rights & Permissions [Opens in a new window]

Abstract

Multidrug resistant organisms (MDROs) are a public health threat that have reduced the effectiveness of many available antibiotics. Antimicrobial stewardship programs (ASPs) have been tasked with reducing antibiotic use and therefore the emergence of MDROs. While fecal microbiota transplant (FMT) has been proposed as therapy to reduce patient colonization of MDROs, this will require additional evidence to support an expansion of the current clinical indication for FMT. This article discusses the evidence and ethics of the expanded utilization of FMT by ASPs for reasons other than severe recurrent or refractory Clostridioides (formerly Clostridium) difficile infection.

Type
Symposium 1 Articles
Information
Journal of Law, Medicine & Ethics , Volume 47 , Issue 4: Symposium 1 - The Promise and Challenges of Microbiome-based Therapies. Symposium 2 - Regulation on International Direct-to-Participant Genomic Research , Winter 2019 , pp. 541 - 554
Copyright
Copyright © American Society of Law, Medicine and Ethics 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Levy, S.B. and Marshall, B., “Antibacterial Resistance Worldwide: Causes, Challenges and Responses,” Nature Medicine 10, no. 12 Suppl (2004): S122–129, available at <https://www.ncbi.nlm.nih.gov/pubmed/15577930> (last visited September 23, 2019); Lobanovska, M. and Pilla, G, “Penicillin's Discovery and Antibiotic Resistance: Lessons for the Future?” Yale Journal of Biology and Medicine 90, no. 1 (2017): 135–145.CrossRefGoogle Scholar
Id.Google Scholar
Levy and Marshall, supra note 1; Lobanovska and Pilla, supra note 1; Ventola, C.L., “The Antibiotic Resistance Crisis. Part 1: Causes and Threats,” P&T 40, no. 4 (2015): 277–283.Google Scholar
Chen, L.,Todd, R., Kiehlbauch, J., Walters, M., and Kallen, A. J., “Pan-Resistant New Delhi Metallo-Beta-Lactamase-Producing Klebsiella pneumoniae-Washoe County, Nevada, 2016,” MMWR 60, no. 1 (2017): 33; Sonnevend, A., Ghazawi, A., Hashmey, R., Haidermota, A., Girgis, S., Alfaresi, M., Omar, M., Paterson, D. L., Zowawi, H. M, and Pal, T., “Multihospital Occur-rence of Pan-Resistant Klebsiella pneumoniae Sequence Type 147 with an ISEcp1-Directed blaOXA-181 Insertion in the mgrB Gene in the United Arab Emirates,” Antimicrob Agents Chemother 61, no. 7 (2017): e00418–17, available at <https://doi.org/10.1128/AAC.00418-17> (last visited September 24, 2019).Google Scholar
Sonnevend, A., Ghazawi, A., Hashmey, R., Haidermota, A., Girgis, S., Alfaresi, M., Omar, M., Paterson, D. L., Zowawi, H. M., and Pal, T., “Multihospital Occurrence of Pan-Resistant Klebsi-ella pneumoniae Sequence Type 147 with an ISEcp1-Directed blaOXA-181 Insertion in the mgrB Gene in the United Arab Emirates,” Antimicrob Agents Chemother 61, no. 7 (2017), available at <https://doi.org/10.1128/AAC.00418-17> (last visited September 24, 2019); Cassone, M. and Mody, L., “Colonization with Multi-Drug Resistant Organisms in Nursing Homes: Scope, Importance, and Management,” Current Geriatrics Report 4, no. 1 (2015): 87–95, available at <https://doi.org/10.1007/s13670-015-0120-2> (last visited September 24, 2019); Guh, A. Y., Bulens, S. N., Mu, Y., Jacob, J. T., Reno, J., Scott, J., Wilson, L. E., Vaeth, E., Lynfield, R., Shaw, K. M., Vagnone, P. M., Bamberg, W. M., Janelle, S. J., Dumyati, G., Concannon, C., Beldavs, Z., Cunningham, M., Cassidy, P. M., Phipps, E. C., Kenslow, N., Travis, T., Lonsway, D., Rasheed, J. K., Limbago, B. M., and Kallen, A. J., “Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013,” JAMA 314, no. 14 (2015): 1479–1487, available at <https://doi.org/10.1001/jama.2015.12480> (last visited September 24, 2019).CrossRefGoogle Scholar
World Health Organization, “Antimicrobial resistance Global Report on surveillance,” available at <https://www.who.int/drugresistance/documents/surveillancereport/en/> (last visited September 24, 2019).+(last+visited+September+24,+2019).>Google Scholar
Dellit, T.H., Owens, R.C., McGowan, J.E. Jr, Gerding, D.N., Weinstein, R.A., Burke, J.P., Huskins, C., Peterson, D.L., Fish-man, N.O., Carpenter, C.F., Brennan, P.J., Billeter, M, and Hooton, T.M., “Infectious Disease Society of America and the Society for Healthcar Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stew-ardship,” Clinical Infectious Diseases 44, no. 2 (2007): 159–177.CrossRefGoogle Scholar
CDC, “Core Elements of Antimicrobial Stewardship Programs,” 2014, available at <https://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html> (last visited September 24, 2019).+(last+visited+September+24,+2019).>Google Scholar
Dellit et al., supra note 7.Google Scholar
Id.Google Scholar
Dellit et al., supra note 7; Leuthner, K.D. and Doern, G. V., “Antimicrobial Stewardship Programs,” Journal of Clinical Microbiology 51, no. 12 (2013): 3916–3920, available at <https://doi.org/10.1128/JCM.01751-13> (last visited September 24, 2019).CrossRefGoogle Scholar
Leuthner and Doern, supra note 11; Dellit et al., supra note 7.Google Scholar
Dellit et al., supra note 7; Leuthner and Doern, supra note 11.Google Scholar
Medicare and Medicaid Programs, Hospital and Critical Access Hospital (CAH) Changes To Promote Innovation, Flexibility, and Improvement in Patient Care, 81 Fed. Reg. 39,448, 39,454-39,459 (proposed June 16, 2016).Google Scholar
Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities, 81 Fed. Reg. 68,688 (Oct. 4, 2016) (to be codified at 42 C.F.R. pt. 483); 42 C.F.R. § 483.80(a)(3) (2018).Google Scholar
Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities, 80 Fed. Reg. 42,167, 42,215 (proposed Jul. 16, 2015) (to be codified at 42 C.F.R. pt. 483).Google Scholar
Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities, 81 Fed. Reg. 68,688, 68,808 (Oct. 4, 2016).Google Scholar
Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities, 81 Fed. Reg. 68,688, 68,808 (Oct. 4, 2016).Google Scholar
Joint Commission, “Approved: New Antimicrobial Steward-ship Standard,” Joint Commission Perspectives 36, no. 7 (2016): 1–4, available at <https://www.jointcommission.org/assets/1/6/New_Antimicrobial_Stewardship_Standard.pdf> (last visited September 24, 2019).+(last+visited+September+24,+2019).>Google Scholar
Wei, M., State Recognition, Joint Commission Website, available at <https://www.jointcommission.org/state_recognition/state_recognition.aspx> (last visited April 15, 2019).+(last+visited+April+15,+2019).>Google Scholar
Facts About Federal Deemed Status and State Recognition, Joint Commission Website, available at <https://www.joint-commission.org/facts_about_federal_deemed_status_and_state_recognition/> (last visited April 15, 2019).+(last+visited+April+15,+2019).>Google Scholar
Hyun, D., “Delays Hinder Effort to Protect Medicare, Medicaid Patients From Superbugs,” Pew Charitable Trusts, November 9, 2018, available at <https://www.pewtrusts.org/en/research-and-analysis/articles/2018/11/09/delays-hinder-effort-to-protect-medicare-medicaid-patients-from-superbugs> (last visited September 24, 2019).Google Scholar
Joint Commission, “Approved: New Antimicrobial Steward-ship Standard,” Joint Commission Perspectives 36, no. 7 (2016): 1–4, available at <https://www.jointcommission.org/assets/1/6/New_Antimicrobial_Stewardship_Standard.pdf> (last visited September 24, 2019).+(last+visited+September+24,+2019).>Google Scholar
Medicare and Medicaid Programs, Hospital and Critical Access Hospital (CAH) Changes To Promote Innovation, Flexibility, and Improvement in Patient Care; Extension of Time-line for Publication of the Final Rule, 84 Fed. Reg. 27,069 (June 11, 2019).Google Scholar
Pettigrew, M.M., Johnson, J. K, and Harris, A. D., “The Human Microbiota: Novel Targets for Hospital-Acquired Infections and Antibiotic Resistance,” Annals of Epidemiology 26, no. 5 (2016): 342–347, available at <https://doi.org/10.1016/j.annepidem.2016.02.007> (last visited September 24, 2019); Tosh, P.K. and McDonald, L.C., “Infection Control in the Multidrug-Resistant Era: Tending the Human Microbiome,” Clinical Infectious Diseases 54, no. 4 (2012): 707–713.CrossRefGoogle Scholar
M.M. Pettigrew et al., supra note 25, Tosh and McDonald, supra note 25.Google Scholar
Mullish, B.H., Quraishi, M. N, Segal, J. P, McCune, V. L, Baxter, M., Marsden, G. L, Moore, D. J, Colville, A., Bhala, N., Iqbal, T. H, Settle, C., Kontkowski, G., Hart, A. L, Hawkey, P. M, Goldenberg, S. D, and Williams, H. R. T., “The Use of Faecal Microbiota Transplant as Treatment for Recurrent or Refractory Clostridium Difficile Infection and Other Potential Indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) Guidelines,” Gut 67, no. 11 (2018): 1920–1941, available at <https://doi.org/10.1136/gutjnl-2018-316818> (last visited September 24, 2019).CrossRefGoogle Scholar
Martin, D., Muñoz, R., Yoder, K., Allegretti, J. R, Smith, M., and Kassam, Z., “Sa1093 Assessing the Landscape of Fecal Micro-biota Transplantation Programs for Recurrent Clostridium difficile Infection: A Survey of Existing Practices Among Healthcare Centers Using an International Public Stool Bank,” Gastroenterology 150, no. 4 (2016): S238, available at <https://doi.org/10.1016/s0016-5085(16)30866-6> (last visited September 24, 2019).CrossRefGoogle Scholar
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G, de Vos, W. M, Visser, C. E, Kuijper, E. J, Bartelsman, J. F, Tijssen, J. G, Speelman, P., Dijkgraaf, M. G, and Keller, J. J, “Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile,” New England Journal of Medicine 368, no. 5 (2013): 407–415, available at <https://doi.org/10.1056/NEJMoa1205037> (last visited September 24, 2019); Shogbesan, O., Poudel, D. R, Victor, S., Jehangir, A., Fadahunsi, O., Shogbesan, G., and Donato, A., “A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients,” Canadian Journal of Gastroenterology and Hepatology (2018): 1394379, available at <https://doi.org/10.1155/2018/1394379> (last visited September 24, 2019).CrossRefGoogle Scholar
Shogbesan, supra note 29.Google Scholar
Shogbesan, supra note 29; van Nood et al., supra note 29.Google Scholar
Mullish, supra note 27.Google Scholar
Grima, D.T., Webb, G. F, and D'Agata, E. M, “Mathematical Model of the Impact of a Nonantibiotic Treatment for Clostridium difficile on the Endemic Prevalence of Vancomycin-Resistant Enterococci in a Hospital Setting,” Computational and Mathematical Methods in Medicine (2012): 605861, availkable at <https://doi.org/10.1155/2012/605861> (last visited September 24, 2019).Google Scholar
Lahtinen, P. et al., “Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications: A case series,” World Journal Gastroenterology 23, no. 39: 7174–7184.CrossRefGoogle Scholar
Laffin, M., Millan, B., and Madsen, K. L, “Fecal Microbial Transplantation as a Therapeutic Option in Patients Colonized with Antibiotic Resistant Organisms,” Gut Microbes 8, no. 3: 221–224, available at <https://doi.org/10.1080/19490976.2016.1278105> (last visited September 24, 2019); Vehres-child, M. J et al., “A Multicentre Cohort Study on Colonization and Infection with ESBL-Producing Enterobacteriaceae in High-Risk Patients with Haematological Malignancies,” Journal of Antimicrobial Chemotherapy 69, no. 12 (2014): 3387–3392, available at <https://doi.org/10.1093/jac/dku305> (last visited September 24, 2019).CrossRefGoogle Scholar
Tacconelli, E., Mazzaferri, F., de Smet, A. M, Bragantini, D., Eggimann, P., Huttner, B. D, Kuijper, E. J, Lucet, J. C, Mutters, N. T, Sanguinetti, M., Schwaber, M. J, Souli, M., Torre-Cisneros, J., Price, J. R, and Rodriguez-Bano, J., “ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers,” Clinical Microbiology and Infection (2019), available at <https://doi.org/10.1016/j.cmi.2019.01.005> (last visited September 24, 2019); Vehres-child et al., supra note 35.Google Scholar
Stewardson, A.J. et al., “The Health and Economic Burden of Bloodstream Infections Caused by Antimicrobial-Susceptible and Non-Susceptible Enterobacteriaceae and Staphylococcus Aureus in European Hospitals, 2010 and 2011: A Multi-centre Retrospective Cohort Study,” Eurosurveillance 21, no. 33 (2016), available at <https://doi.org/10.2807/1560-7917.ES.2016.21.33.30319> (last visited September 25, 2019); Barrasa-Villar, J.I. et al., “Impact on Morbidity, Mortality, and Length of Stay of Hospital-Acquired Infections by Resistant Microorganisms,” Clinical Infectious Diseases 65, no. 4 (2017): 644–652, available at <https://doi.org/10.1093/cid/cix411> (last visited September 25, 2019).CrossRefGoogle Scholar
Millan, B. et al., “Fecal Microbial Transplants Reduce Antibiotic-Resistant Genes in Patients With Recurrent Clostridium difficile Infection,” Clinical Infectious Diseases 62, no. 12 (2016): 1479–1486, available at <https://doi.org/10.1093/cid/ciw185> (last visited September 25, 2019).CrossRefGoogle Scholar
Id.Google Scholar
Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., and Wang, B., “Systematic Review: Adverse Events of Fecal Microbiota Transplantation,” PLoS One 11, no. 8: e0161174, available at <https://doi.org/10.1371/journal.pone.0161174> (last visited September 25, 2019); Baxter, M. and Colville, A., “Adverse Events in Faecal Microbiota Transplant: A Review of the Literature,” Journal of Hospital Infection 92, no. 2 (2016): 117–127, available at <https://doi.org/10.1016/j.jhin.2015.10.024> (last visited September 26, 2019).Google Scholar
Ma, Y., Liu, J., Rhodes, C., Nie, Y., and Zhang, F., “Ethical Issues in Fecal Microbiota Transplantation in Practice,” American Journal of Bioethics 17, no. 5 (2017): 34–45; Rhodes, R. and Sacks, H., “Cautions for Extending Fecal Microbiota Transplantation to Other Therapeutic Uses,” American Journal of Bioethics 17, no. 5 (2017): 46–48, available at <https://doi.org/10.1080/15265161.2017.1299251> (last visited September 26, 2019); Woodworth, M. H et al., “Ethical Considerations in Microbial Therapeutic Clinical Trials,” The New Bioethics 23, no. 3 (2017): 210–218, available at <https://doi.org/10.1080/20502877.2017.1387386> (last visited September 26, 2019).CrossRefGoogle Scholar
Leung, V., Vincent, C., Edens, T. J, Miller, M., and Manges, A. R, “Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection,” Clinical Infectious Diseases 66, no. 3 (2018): 456–457, available at <https://doi.org/10.1093/cid/cix821> (last visited September 26, 2019).CrossRefGoogle Scholar
Mullish, supra note 27.Google Scholar
U.S. Food & Drug Admin., Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms, June 13, 2019, available at <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiotatransplantation-and-risk-serious-adverse> (last visited September 26, 2019).+(last+visited+September+26,+2019).>Google Scholar
Ma, supra note 41; Rhodes, supra note 41.Google Scholar
Childress, J. F and Beauchamp, T. L, Principles of Biomedical Ethics. 7th ed. (New York, NY: Oxford University Press, 2013).Google Scholar
Jonsen, A. R, Siegler, M., and Winslade, W. J, Clinical Ethics: A Practical Approach to Ethical Decisions in Clinical Medicine 8th ed. (McGraw-Hill Education, 2015).Google Scholar
Ma, Y., Liu, J., Rhodes, C., Nie, Y., and Zhang, F., “Ethical Issues in Fecal Microbiota Transplantation in Practice,” American Journal of Bioethics 17, no. 5 (2017): 34–45, available at <https://doi.org/10.1080/15265161.2017.1299240> (last visited September 26, 2019); Rhodes, supra note 41.CrossRefGoogle Scholar
Tacconelli, E. et al., “ESCMID-EUCIC Clinical Guidelines on Decolonization of Multidrug-Resistant Gram-Negative Bacteria Carriers,” Clinical Microbiology and Infection 25, no. 7 (2019), available at <https://doi.org/10.1016/j.cmi.2019.01.005> (last visited September 26, 2019).CrossRefGoogle Scholar
M.J. Vehreschild et al., supra note 35.Google Scholar
M. Laffin, supra note 35.Google Scholar
Davido, B., Batista, R., Michelon, H., Lepainteur, M., Bouchand, F., Lepeule, R., Salomon, J., Vittecoq, D., Duran, C., Escaut, L., Sobhani, I., Paul, M., Lawrence, C., Perronne, C., Chast, F., and Dinh, A., “Is Faecal Microbiota Transplantation an Option to Eradicate Highly Drug-Resistant Enteric Bacteria Carriage?” Journal of Hospital Infection 95, no. 4 (2017): 433–437, available at <https://www.ncbi.nlm.nih.gov/pubmed/28237504> (last visited December 5, 2019).CrossRefGoogle Scholar
Id.Google Scholar
Bilinski, J. et al., “Fecal Microbiota Transplantation in Patients With Blood Disorders Inhibits Gut Colonization With Antibiotic-Resistant Bacteria: Results of a Prospective, Single-Center Study,” Clinical Infectious Diseases 65, no. 3 (2017): 364–370, available at <https://doi.org/10.1093/cid/cix252> (last visited September 26, 2019).CrossRefGoogle Scholar
Davido, supra note 52; Bilinski, supra note 54.Google Scholar
clinicaltrials.gov, (search terms “fecal microbiota,” “MDRO” and “Fecal Transplantation for primary Clostridium infection”), (last visited April 15, 2019).Google Scholar
Mullish, supra note 27; U.S. Food & Drug Admin., supra note 44.Google Scholar
Rolston, K., “Infections in Cancer Patients with Solid Tumors: A Review,” Infectious Diseases and Therapies 6, no. 1 (2017): 69–83, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336421/> (last visited September 26, 2019).CrossRefGoogle Scholar
Shogbesan, supra note 29; Webb, B.J., Brunner, A., Ford, C. D, Gazdik, M. A, Petersen, F. B, and Hoda, D., “Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Hematopoietic Stem Sell Transplant Recipients,” Transplant Infectious Disease 18, no. 4 (2016): 628–633, available at <https://doi.org/10.1111/tid.12550> (last visited September 26, 2019).CrossRefGoogle Scholar
Kelly, C.R. et al., “Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients,” American Journal of Gastroenterology 109, no. 7 (2014): 1065–1071, available at <https://doi.org/10.1038/ajg.2014.133> (last visited September 26, 2019).CrossRefGoogle Scholar
Cheng, Y. W et al., “Fecal Microbiota transplantation for the Treatment of Recurrent and Severe Clostridium difficile Infection in Solid Organ Transplant Recipients: A Multi-center Experience,” American Journal of Transplantation 19, no. 2 (2019): 501–511, available at <https://doi.org/10.1111/ajt.15058> (last visited September 26, 2019).CrossRefGoogle Scholar
Id.Google Scholar
Friedman-Korn, T. et al., “Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients,” Digestive Diseases and Sciences 63, no. 1 (2018): 198–203, available at <https://doi.org/10.1007/s10620-017-4833-2> (last visited September 26, 2019).CrossRefGoogle Scholar
El-Saifi, N., Moyle, W., and Jones, C., “Medication Adherence in Older Patients with Dementia: A Systematic Literature Review,” Journal of Pharmacy Practice 31, no. 3 (2017): 322–334, available at <https://doi.org/10.1177/0897190017710524> (last visited September 27, 2019).CrossRefGoogle Scholar
Bunnell, K.L., Danziger, L. H, and Johnson, S., “Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin,” Open Forum Infectious Diseases 4, no. 2 (2017): ofx078, available at <https://doi.org/10.1093/ofid/ofx078> (last visited September 27, 2019).CrossRefGoogle Scholar
Id.Google Scholar
Varier, R. U, Biltaji, E., Smith, K. J, Roberts, M. S, Jensen, M. K, LaFleur, J., and Nelson, R. E, “Cost-Effectiveness Analysis of Treatment Strategies for Initial Clostridium difficile Infection,” Clinical Microbiology and Infection 20, no. 12 (2014): 1343–1351, available at <https://doi.org/10.1111/1469-0691.12805> (last visited September 27, 2019).CrossRefGoogle Scholar
Id.Google Scholar
Denton, A., Topping, A., and Humphreys, P., “Managing Clostridium difficile Infection in Hospitalised Patients,” Nursing Standard 28, no. 33 (2014): 37–43, available at <https://doi.org/10.7748/ns2014.04.28.33.37.e8461> (last visited September 27, 2019).Google Scholar
Juul, F. E et al., “Fecal Microbiota Transplantation for Primary Clostridium difficile Infection,” New England Journal of Medicine 378, no. 26 (2018): 2535–2536, available at <https://doi.org/10.1056/NEJMc1803103> (last visited September 27, 2019).CrossRefGoogle Scholar
Id.Google Scholar
Clinicaltrials.gov, supra note 56.Google Scholar
Brody, H., “Shared Decision Making and Determining Decision-Making Capacity,” Primary Care: Clinics in Office Practice 32, no. 3 (2005): 645–658, available at <https://doi.org/10.1016/j.pop.2005.06.004> (last visited September 27, 2019).CrossRefGoogle Scholar
Kahn, S.A., Gorawara-Bhat, R., and Rubin, D. T, “Fecal Bacteriotherapy for Ulcerative Colitis: Patients are Ready, Are We?” Inflammatory Bowel Diseases 18, no. 4: 676–684; Kahn, S.A., Vachon, A., Rodriquez, D., Goeppiger, S. R, Surma, B., Marks, J., and Rubin, D. T, “Patient Perceptions of Fecal Microbiota Transplantation for Ulcerative Colitis,” Inflammatory Bowel Diseases 19, no. 7 (2013): 1506–1513, available at <https://doi.org/10.1097/MIB.0b013e318281f520> (last visited December 6, 2019).CrossRefGoogle Scholar
Park, L., Mone, A., Price, J. C, Tzimas, D., Hirsh, J., Poles, M. A, Malter, L., and Chen, L. A, “Perceptions of Fecal Microbiota Transplantation for Clostridium difficile Infection: Factors that Predict Acceptance,” Annals of Gastroenterology 30, no. 1 (2017): 83–88, available at <https://doi.org/10.20524/aog.2016.0098> (last visited September 27, 2019).Google Scholar
Ma, supra note 48; Rhodes, supra note 41.Google Scholar
Unguru, Y., “Pediatric decision-making: informed consent, parental permission, and child assent,” in Clinical Ethics in Pediatrics: A Case-Based Textbook, edited by Diekema, D. S et al. (Cambridge University Press, 2011): 1–6.Google Scholar
Kahn, S., Nicholson, M. and Gulati, A., “Use of FMT in the pediatric population: Safety, Efficacy and Ethical issues for the practitioner,” previously presented during the working group for this symposium.Google Scholar
H. Brody, supra note 73.Google Scholar
Bean, S., “Navigating the Murky Intersection Between Clinical and Organizational Ethics: A Hybrid Case Taxonomy,” Bioethics 25, no. 6 (2011): 320–325, available at <https://doi.org/10.1111/j.1467-8519.2009.01783.x> (last visited September 27, 2019).Google Scholar
Silva, D., Gibson, J., Sibbald, R., Connolly, E., and Singer, P. A, “Clinical Ethicists' Perspectives on Organisational Ethics in Healthcare Organisations,” Journal of Medical Ethics 34, no. 5 (2008): 320–323; Gibson, J.L., Sibbald, R., Connolly, E., and Singer, P., “Organizational Ethics,” in The Cambridge Textbook of Bioethics, edited by Singer, P. A and Viens, A. M. (Cambridge University Press, 2008).CrossRefGoogle Scholar
Jump, R.L.P., Gaur, S., Katz, M. J, Crnich, C. J, Dumyati, G., Ashraf, M. S, Frentzel, E., Schweon, S. J, Sloane, P., and Nace, D., “Template for an Antibiotic Stewardship Policy for Post-Acute and Long-Term Care Settings,” Journal of the American Medical Directors Association 18, no. 11 (2017): 913–920, available at <https://doi.org/10.1016/j.jamda.2017.07.018> (last visited September 27, 2019).CrossRefGoogle Scholar
Institute for Healthcare Improvement, “The IHI Triple Aim,” available at <http://www.ihi.org/Engage/Initiatives/TripleAim/Pages/default.aspx> (last visited September 27, 2019).+(last+visited+September+27,+2019).>Google Scholar
Tosh, P.K. and McDonald, L.C., “Infection Control in the Multidrug-Resistant Era: Tending the Human Microbiome,” Clinical Infectious Diseases 54, no. 4 (2012): 707–713.CrossRefGoogle Scholar
O'Doherty, K.C., Virani, A., and Wilcox, E. S, “The Human Microbiome and Public Health: Social and Ethical Considerations,” American Journal of Public Health 106, no. 3 (2016): 414–420, available at <https://doi.org/10.2105/ajph.2015.302989> (last visited September 27, 2019).Google Scholar
Waye, A., Atkins, K., and Kao, D., “Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada,” Journal of Clinical Gastroenterology 50, no. 9 (2016): 747–753, available at <https://doi.org/10.1097/mcg.0000000000000494> (last visited September 27, 2019); Varier, R.U., Biltaji, E., Smith, K. J, Roberts, M. S, Jensen, M. K, LaFleur, J., and Nelson, R. E, “Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection,” Clinical Microbiology and Infection 20, no. 12 (2014): 1343–1351, available at <https://doi.org/10.1111/1469-0691.12805> (last visited September 27, 2019); Varier, R. U, Biltaji, E., Smith, K. J, Roberts, M. S, Kyle Jensen, M., LaFleur, J., and Nelson, R. E. “Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection,” Infection Control and Hospital Epidemiology 36, no. 4 (2015): 438–444, available at <https://doi.org/10.1017/ice.2014.80> (last visited September 27, 2019).CrossRefGoogle Scholar
Waye, A., Atkins, K., and Kao, D., “Cost Averted With Timely Fecal Microbiota Transplantation in the Management of Recurrent Clostridium difficile Infection in Alberta, Canada,” Journal of Clinical Gastroenterology 50, no. 9 (2016): 747–753, available at <https://doi.org/10.1097/mcg.0000000000000494> (last visited September 27, 2019).CrossRefGoogle Scholar
Rhodes, supra note 41; American Gastroenterological Association, Fecal Microbiota Transplantation National Registry, available at <https://www.gastro.org/research-and-awards/registries-and-studies/fecal-microbiota-transplantation-fmt-national-registry> (last visited September 27, 2019).+(last+visited+September+27,+2019).>Google Scholar
Kullar, R., Vassallo, A., Turkel, S., Chopra, T., Kaye, K. S, and Dhar, S., “Degowning the controversies of contact precautions for methicillin-resistant Staphylococcus aureus: A review,” American Journal of Infection Control 44, no. 1 (2016): 97–103, available at <https://doi.org/10.1016/j.ajic.2015.08.003> (last visited September 27, 2019).CrossRefGoogle Scholar
45 C.F.R. § 46.102(l) (2018).Google Scholar
45 C.F.R. § 46.102(e)(1)(ii) (2018).Google Scholar
45 C.F.R. § 46.101(a) (2018).Google Scholar
45 C.F.R. § 46.102(l) (2018).Google Scholar
U.S. Food & Drug Admin., “Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies,” March 2016, available at <https://www.fda.gov/media/96562/download> (last visited September 27, 2019).+(last+visited+September+27,+2019).>Google Scholar
21 C.F.R. § 312.40(a) (2018).CrossRefGoogle Scholar
21 C.F.R. Part 50 (2018).Google Scholar
21 C.F.R. Part 56 (2018).CrossRefGoogle Scholar
Khoruts, A., Hoffmann, D. E, and Palumbo, F.P., “The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation,” Journal of Law, Medicine & Ethics 47, no. 4 (2019): 482–504.Google Scholar
Supported in work by McGovern, Hecht, and Wilcox, presented during the working group for this symposium.Google Scholar
21 C.F.R. Part 50 (2018); 21 C.F.R. § 312.40(a) (2018).CrossRefGoogle Scholar
Mullish, supra note 27; Woodworth, M.H., Neish, E. M, Miller, N. S, Dhere, T., Burd, E. M, Carpentieri, C., Sitchenko, K. L, and Kraft, C. S, “Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection,” Journal of Clinical Micro-biology 55, no. 4 (2017): 1002–1010, available at <https://doi.org/10.1128/JCM.02327-16> (last visited September 27, 2019); U.S. Food & Drug Admin., Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms, June 13, 2019, available at <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse> (last visited September 27, 2019).CrossRefGoogle Scholar
Protection of Human Subjects, 45 C.F.R. part 46 (2018).Google Scholar
Freedman, B., “Equipoise and the Ethics of Clinical Research,” New England Journal of Medicine 317, no. 3 (1987): 141–145, available at <https://doi.org/10.1056/nejm198707163170304> (last visited September 27, 2019); Hey, S. P, Weijer, C., Taljaard, M., and Kesselheim, A. S, “Research Ethics for Emerging Trial Designs: Does Equipoise Need to Adapt?” BMJ 360 (2018): k226, available at <https://doi.org/10.1136/bmj.k226> (last visited September 27, 2019).CrossRefGoogle Scholar
Jongsma, K., Bos, W., and van de Vathorst, S.. “Morally Relevant Similarities and Differences Between Children and Dementia Patients as Research Subjects: Representation in Legal Documents and Ethical Guidelines,” Bioethics 29, no. 9 (2015): 662–670, available at <https://doi.org/10.1111/bioe.12195> (last visited September 27, 2019).CrossRefGoogle Scholar
Id.Google Scholar
Id.Google Scholar
45 C.F.R. § 46.405 (2018).CrossRefGoogle Scholar
45 C.F.R. § 46.116 (2018).CrossRefGoogle Scholar
Jongsma, supra note 104.Google Scholar
Jongsma, supra note 104.Google Scholar
Jongsma, supra note 104.Google Scholar
Jongsma, supra note 104.Google Scholar
Woodworth, M.H., Sitchenko, K. L, Carpentieri, C., Friedman-Moraco, R. J, Wang, T., and Kraft, C. S, “Ethical Considerations in Microbial Therapeutic Clinical Trials,” The New Bioethics 23, no. 3 (2017): 210–218, available at <https://doi.org/10.1080/20502877.2017.1387386> (last visited September 27, 2019).CrossRefGoogle Scholar